Dynavax Technologies Corp (DVAX) Drops 7.03% on January 12

Equities Staff |

Dynavax Technologies Corp (DVAX) was one of the Russell 2000's biggest losers for Tuesday January 12 as the stock slid 7.03% to $23.27, a loss of $-1.76 per share. Starting at an opening price of $25.30 a share, the stock traded between $22.26 and $26.33 over the course of the trading day. Volume was 1.23 million shares over 9,093 trades, against an average daily volume of 685,035 shares and a total float of 38.43 million.

The losses send Dynavax Technologies Corp down to a market cap of $894.16 million. In the last year, Dynavax Technologies Corp has traded between $32.49 and $15.80, and its 50-day SMA is currently $25.50 and 200-day SMA is $25.03.

Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The Company is engaged in the development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer.

Dynavax Technologies Corp is based out of Berkeley, CA and has some 197 employees. Its CEO is Eddie Gray.

For a complete fundamental analysis analysis of Dynavax Technologies Corp, check out Equities.com’s Stock Valuation Analysis report for DVAX. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…